Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow IPSC by emailGet an email when IPSC pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about IPSC, unsubscribe in one click. Privacy
📣 What IPSC Says Is Next
fourth quarter of 2026 · “CNTY-813, an iPSC-derived islet replacement therapy for T1D, remains on track for an IND submission in the fourth quarter of 2026, following a pre-IND meeting with the FDA that yielded alignment on the nonclinical data package, manufacturing strategy, and proposed Phase 1/2 trial design.”
Company press release, Sep 9, 2026 · SEC filing
4Q 2026 · “Next-gen discovery programs across multiple cell types and targets Recent Funding Oversubscribed $135M PIPE in early 2026 provides runway into Q1 2029 Key Anticipated Near-Term Milestones ❑ CNTY-813 oral presentation at EASD 2026 ❑ CNTY-813 IND submission expected 4Q 2026 ❑ CNTY-308 expected in clinic in 2026 ❑ Clinical data expected 2H 2027 for CNTY-813 Focused.”
Company press release, Aug 12, 2026 · SEC filing
in 2026 · “CNTY-308 is anticipated to enter the clinic in 2026. · Preclinical data showed functional comparability to primary CAR - T cells, including target - driven proliferation, cytokine secretion, and durable persistence.”
Company press release, Aug 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full IPSC picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IPSC and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.